Revenue growth has collapsed to -100% for multiple consecutive quarters, reflecting a total abandonment of commercial operations in favor of an unproven regulatory-first strategy.
| Sales/Revenue | 0 | 0 | 5.11M | 5.82M | 5.99M | 7.81M | 9.56M | 15.58M | 14.05M |
| Revenue Growth % | -100% | -100% | -12.2% | -2.83% | -23.29% | -18.29% | -38.63% | 10.86% | - |
| Cost of Goods Sold | 0 | 0 | 1.21M | 1.63M | 2.29M | 1.6M | 4.05M | 12.72M | 10.48M |
| COGS % of Revenue | - | - | 23.72% | 28.02% | 38.21% | 20.48% | 42.33% | 81.65% | 74.59% |
| Gross Profit | 0 | 0 | 3.9M | 4.19M | 3.7M | 6.21M | 5.51M | 2.86M | 3.57M |
| Gross Margin % | - | - | 76.28% | 71.98% | 61.79% | 79.52% | 57.67% | 18.35% | 25.41% |
| Gross Profit Growth % | - | -100% | -6.96% | 13.19% | -40.39% | 12.67% | 92.83% | -19.93% | - |
| Operating Expenses | 4.21M | 4.64M | 21.58M | 17.81M | 23.62M | 24.26M | 22.8M | 25.02M | 11.22M |
| OpEx % of Revenue | - | - | 422.12% | 305.86% | 394.16% | 310.57% | 238.46% | 160.61% | 79.86% |
| Selling, General & Admin | 3.22M | 4.64M | 8.75M | 9.26M | 12.21M | 15.59M | 15.67M | 19.73M | 11.22M |
| SG&A % of Revenue | - | - | 171.15% | 159.07% | 203.76% | 199.63% | 163.97% | 126.64% | 79.86% |
| Research & Development | 0 | 0 | 2.62M | 2.41M | 1.74M | 1.79M | 459.64K | 0 | 0 |
| R&D % of Revenue | - | - | 51.15% | 41.38% | 29.04% | 22.9% | 4.81% | - | - |
| Other Operating Expenses | 990.74K | 0 | 10.21M | 6.14M | 9.67M | 6.88M | 6.66M | 5.29M | 0 |
| Operating Income | -4.21M | -4.64M | -17.68M | -13.62M | -19.92M | -18.05M | -17.28M | -19.31M | -7.65M |
| Operating Margin % | - | - | -345.84% | -233.88% | -332.37% | -231.05% | -180.78% | -123.98% | -54.45% |
| Operating Income Growth % | - | 73.75% | -29.83% | 31.63% | -10.35% | -4.43% | 10.51% | -152.44% | - |
| EBITDA | -3.46M | -4.64M | -14.74M | -10.2M | -14.2M | -11.17M | -10.53M | -14.02M | 414.72K |
| EBITDA Margin % | - | - | -288.26% | -175.22% | -236.98% | -143% | -110.14% | -90.01% | 2.95% |
| EBITDA Growth % | 73.48% | 68.5% | -44.44% | 28.15% | -27.12% | -6.09% | 24.91% | -3480.83% | - |
| D&A (Non-Cash Add-back) | 707.8K | 0 | 2.94M | 3.42M | 5.72M | 6.88M | 6.75M | 5.29M | 8.06M |
| EBIT | -4.1M | -4.64M | -13.76M | -7.63M | -19.44M | -8.62M | -18.96M | -19.31M | -20.63M |
| Net Interest Income | 249.29K | 256.93K | -189.14K | -20.83K | -581.82K | -368.66K | -3.05M | -13.84M | 0 |
| Interest Income | 249.29K | 256.93K | 371.77K | 515.31K | 14.19K | 0 | 0 | 0 | 11.86M |
| Interest Expense | 0 | 0 | 560.91K | 536.14K | 596.02K | 368.66K | 3.05M | 13.84M | 0 |
| Other Income/Expense | -77.36K | 141.31K | 3.36M | 5.45M | -121.82K | 9.06M | -4.73M | -13.84M | -24.84M |
| Pretax Income | -4.29M | -4.5M | -14.32M | -8.16M | -20.04M | -8.99M | -22.01M | -33.16M | -32.49M |
| Pretax Margin % | - | - | -280.1% | -140.2% | -334.4% | -115.05% | -230.27% | -212.86% | -231.2% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | -1.43M | -645.87K | -13.37K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 6.48% | 1.95% | 0.04% |
| Net Income | 3.19M | 1.91M | -14.32M | -8.16M | -20.04M | -8.99M | -20.59M | -32.51M | -32.47M |
| Net Margin % | - | - | -280.1% | -140.2% | -334.4% | -115.05% | -215.35% | -208.71% | -231.1% |
| Net Income Growth % | 122.1% | 113.36% | -75.41% | 59.26% | -122.97% | 56.35% | 36.68% | -0.12% | - |
| Net Income (Continuing) | -4.29M | -4.5M | -14.32M | -8.16M | -20.04M | -8.99M | -20.59M | -32.51M | -32.47M |
| Discontinued Operations | 1.5M | 6.41M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.07 | -1.56 | -3.34 | -6.35 | -9.68 | -8.25 | -38.55 | -132.16 | -324.73 |
| EPS Growth % | 169.63% | 53.29% | 47.4% | 34.4% | -17.33% | 78.6% | 70.83% | 59.3% | - |
| EPS (Basic) | - | -1.56 | -3.34 | -6.35 | -9.68 | -8.25 | -38.55 | -132.16 | -324.73 |
| Diluted Shares Outstanding | 46.22M | 280.65M | 8.03M | 2.18M | 2.07M | 1.09M | 534.07K | 246K | 100K |
| Basic Shares Outstanding | 46.22M | 280.65M | 8.03M | 1.29M | 2.07M | 1.09M | 534.07K | 246K | 100K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
Binary Regulatory Failure Risk
As indicated by the company's recent financial filings, Petros Pharmaceuticals has experienced a complete cessation of revenue, with growth rates hitting -100% for multiple consecutive quarters, signaling a total abandonment of commercial operations to prioritize the high-stakes regulatory transition of its primary therapeutic asset to OTC status.
The transition from a revenue-generating entity to a pre-revenue clinical-stage firm suggests that management has effectively shuttered legacy sales channels to conserve capital. Investors should interpret this as a binary bet on the FDA's ACNU pathway, as the lack of top-line activity leaves no margin for operational error.
Based on the provided income statement data, the company continues to incur significant SG&A expenses despite the absence of revenue, with quarterly overhead reaching $1.0M in 2026Q1, highlighting the persistent cash burn required to maintain regulatory compliance and professional services during this dormant commercial phase.
The persistence of SG&A costs in the absence of product sales suggests a rigid cost structure that is heavily weighted toward regulatory and administrative overhead. This expense discipline appears focused entirely on the survival of the regulatory project rather than the optimization of operational efficiency.
According to the provided financial data, the company reports a cash balance of over $5.1 billion, a figure that appears fundamentally inconsistent with the firm's micro-cap status and recent history of revenue collapse, necessitating immediate verification of whether these funds are truly available for operational use.
The discrepancy between the reported cash position and the company's operational scale suggests either a significant accounting anomaly or the presence of restricted capital that cannot be deployed for general corporate purposes. Analysts should treat this figure with extreme caution until the nature of these assets is clarified.
While management frames the OTC transition as a structural moat, the company's reliance on a single-molecule strategy, as evidenced by historical SEC filings, exposes shareholders to extreme binary risk should the FDA reject the proposed Actual Use Study data or the ACNU regulatory pathway entirely.
The market's skepticism regarding the company's valuation suggests that the 'regulatory wrapper' around avanafil is not yet viewed as a defensible competitive advantage. If the regulatory milestones are not met, the company lacks a secondary commercial engine to sustain its current cost structure.
Quick answers to the most common questions about buying PTPI stock.
For fiscal year 2025, Petros Pharmaceuticals, Inc. (PTPI) reported total revenue of $0.0M. This represents a 100.0% decline compared to $14.1M in 2018.
Petros Pharmaceuticals, Inc. (PTPI) is profitable, generating $1.9M in net income for the fiscal year ending 2025.